Read by QxMD icon Read

Parkinson's Disease

Satoko Sekimoto, Genko Oyama, Taku Hatano, Fuyuko Sasaki, Ryota Nakamura, Takayuki Jo, Yasushi Shimo, Nobutaka Hattori
Background: We investigated the feasibility and safety of a video-based telemedicine system, delivered via a tablet, in Parkinson's disease (PD). Methods: In a randomized, crossover, open-label pilot trial, we compared a telemedicine period (regular visits every two months with intermediate video calls via an iPad mini) with a control period (regular visits every two months), both lasting 6 months. We included 10 patients diagnosed with PD according to the British Brain Bank criteria, aged 20-75 years...
2019: Parkinson's Disease
Huynh Man Anh, Dao My Linh, Vuu My Dung, Dang Thi Phuong Thao
Parkinson's disease (PD) is a common neurodegenerative disorder and characterized by progressive locomotive defects and loss of dopaminergic neurons (DA neuron). Currently, there is no potent therapy to cure PD, and the medications merely support to control the symptoms. It is difficult to develop an effective treatment, since the PD onset mechanism of PD is still unclear. Oxidative stress is considered as a major cause of neurodegenerative diseases, and there is increasing evidence for the association between PD and oxidative stress...
2019: Parkinson's Disease
Maryam Mehdizadeh, Pablo Martinez-Martin, Seyed-Amirhasan Habibi, Seyed-Mohammad Fereshtehnejad, Amirabas Abasi, Javad Niazi Khatoon, Seyed Hassan Saneii, Ghorban Taghizadeh
Purpose: Since fear of falling may be one of the main problems in people with Parkinson's disease (PD), its assessment with valid tools is necessary in both drug phases. This study was carried out to investigate the psychometric attributes of the Fall Efficacy Scale-International (FES-I) in people with PD, both in On and Off phases. Methods: One hundred twenty-four patients with PD (mean age ± standard deviation, 60.33 ± 12.59 years) were assessed with the FES-I, both in On- and Off-drug phases...
2019: Parkinson's Disease
Maja Kojovic, Andrea Higgins, Pablo Mir, Marjan Jahanshahi
Background: Motivational improvement of movement speed in Parkinson's disease (PD) is observed in life-threatening situations and has been empirically demonstrated in experimental studies using reaction time paradigms. Objectives: To address two clinically relevant questions: first, if in PD, motivational modulation through provision of monetary incentive on a sorting task that approximates performance on everyday life tasks affects movement speed. Second, how this effect is compared between PD patients treated with medication or subthalamic deep brain stimulation...
2019: Parkinson's Disease
Kuo-Hsuan Chang, Chiung-Mei Chen, Yi-Chun Chen, Hon-Chung Fung, Yih-Ru Wu
Previous genome-wide association studies in Caucasian populations suggest that genetic loci in amino acid catabolism may be associated with Parkinson's disease (PD). However, these genetic disease associations were limitedly reported in Asian populations. Herein, we investigated the effect of top three PD-associated genetic variants related to amino acid catabolism in Caucasians listed on the top risk loci identified by meta-analysis of genome-wide association studies in PDGene database, including aminocarboxymuconate-semialdehyde decarboxylase- ( ACMSD- ) transmembrane protein 163 ( TMEM163 ) rs6430538, methylcrotonyl-CoA carboxylase 1 ( MCCC1 ) rs12637471, and branched-chain ketoacid dehydrogenase kinase- ( BCKDK- ) syntaxin 1B ( STX1B ) rs14235, by genotyping 599 Taiwanese patients with PD and 598 age-matched control subjects...
2019: Parkinson's Disease
Jiang-Bing Liu, Jun-Ling Leng, Ying-Ge Wang, Yu Zhang, Tie-Yu Tang, Li-Hong Tao, Xin-Jiang Zhang, Chun-Feng Liu
Background: Nonmotor symptoms (NMS) are prodromal characteristics of Parkinson's disease (PD). The first-degree relatives (FDR) of PD patients had a higher risk of PD and also had more NMS. Objective: To delineate NMS in FDR of patients with different clinical types of PD. Methods: A total of 98 PD probands were recruited; 256 siblings of them were enrolled in the FDR group. Various scales were used to assess NMS, including depression, anxiety, cognitive impairment, insomnia, constipation, excessive daytime sleepiness, rapid eye movement sleep behavior disorder (RBD), and restless legs syndrome (RLS)...
2019: Parkinson's Disease
Cathy C Harro, Amanda Kelch, Cora Hargis, Abigail DeWitt
Introduction: Postural instability is a known contributing factor to balance dysfunction and increased fall risk in those with Parkinson's disease (PD). Computerized posturography employing a force platform system provides objective, quantitative assessments of postural control impairments. This study examines balance performance as measured by force platform (FP) tests in persons with PD compared to age-matched healthy adults. Secondarily, we examine if these FP measures provide diagnostic and clinically meaningful information about the underlying balance impairments in the PD population...
2018: Parkinson's Disease
Haruo Nishijima, Yasuo Miki, Shinya Ueno, Masahiko Tomiyama
Zonisamide is a relatively recent drug for Parkinson's disease. Multiple hypotheses have been proposed to explain the antiparkinsonian effects of zonisamide. However, it is still unclear whether the effect of zonisamide is mainly due to dopaminergic modification in the striatum, or if zonisamide works through nondopaminergic pathways. We conducted the present study to determine the mechanism that is mainly responsible for zonisamide's effects in Parkinson's disease. We examined the effects of zonisamide on motor symptoms in a hemiparkinsonian rat model when administered singly, coadministered with levodopa, a dopamine precursor, or apomorphine, a D1 and D2 dopamine receptor agonist...
2018: Parkinson's Disease
Anna Sauerbier, Anette Schrag, Pablo Martinez-Martin, Lynsey J Hall, Miriam Parry, Laurie K Mischley, Panagiotis Zis, K Ray Chaudhuri
Dietary habits may differ between Parkinson's disease (PD) patients of different ethnicities. The primary aim of this cross-sectional analysis was to compare dietary habits in a multiethnic PD population and investigate potential nonmotor differences. All patients completed a dietary habits questionnaire. Besides basic demographics, patients' motor involvement (Hoehn and Yahr (HY)) and nonmotor symptoms (Nonmotor Symptoms Scale; Hospital Anxiety and Depression Scale) were assessed. 139 PD patients were included (mean age 66...
2018: Parkinson's Disease
Ann-Kristin Folkerts, Miriam E Dorn, Mandy Roheger, Marco Maassen, Janneke Koerts, Oliver Tucha, Mareike Altgassen, Alexander T Sack, Diede Smit, Lena Haarmann, Elke Kalbe
Background: While the efficacy of cognitive stimulation (CS) has been demonstrated in patients with dementia, no study has included patients with Parkinson's disease dementia (PDD). Objective: For the first time, this randomized crossover pilot study examined the feasibility and potential effects of CS in PDD. Methods: All residents of a PDD-specific long-term care unit in the Netherlands that were eligible for the study ( n =12) were randomly allocated to group A ( n =6) receiving CS (eight weeks, twice weekly for 60 minutes) or group B ( n =6) receiving usual care (control group, CG)...
2018: Parkinson's Disease
Emily J Corti, Andrew R Johnson, Natalie Gasson, Romola S Bucks, Meghan G Thomas, Andrea M Loftus
The Ways of Coping Questionnaire (WCQ) is used extensively in health research, but the measurement properties and suitability of the WCQ for people with Parkinson's disease (PD) have not been psychometrically assessed. If the WCQ does not align with its original 8-factor structure in a PD population, the use of the WCQ subscales may not be appropriate. The present study used confirmatory factor analysis (CFA), exploratory factor analysis (EFA), and multiple-group EFA to determine the ideal factor structure of the WCQ in a PD sample...
2018: Parkinson's Disease
Li Shu, Dongxiao Liang, Hongxu Pan, Qian Xu, Xinxiang Yan, Beisha Tang, Qiying Sun
Inflammation has been demonstrated to be involved in Parkinson's disease (PD) pathogenesis. There were evidences that the disturbance of the protective function of IL-10 gene contributed to PD. In our study, haplotype analyses were conducted of IL-10 rs1800871 and rs1800872 on 371 PD patients. Because the two SNPs exposed significant linkage disequilibrium demonstrated by Haploview software, we included 177 carriers of both rs1800871 and rs1800872 and 190 noncarriers in clinical phenotype analyses. As to nonmotor symptoms, the score of the gastrointestinal dysfunction domain in Nonmotor Symptom Scale (NMSS) was lower in the carrier group of both SNPs than in the noncarrier group in PD patients (SC: -0...
2018: Parkinson's Disease
Li Shu, Dongxiao Liang, Hongxu Pan, Qian Xu, Jifeng Guo, Qiying Sun, Beisha Tang, Xinxiang Yan
SNCA -rs11931074 had been demonstrated to be strongly correlated with PD risk. However, there was lack of comprehensive analysis of SNCA -rs11931074-related clinical features which may help explain clinical heterogeneity of PD. In our study, we performed association analyses on the relationship between SNCA -rs11931074 and motor symptoms, nonmotor symptoms, and comorbidities in PD. 611 rs11931074 carriers and 113 rs11931074 noncarriers were enrolled. In the clinical phenotype analyses, the Unified Parkinson's Disease Rating Scale part II (UPDRS II) and part III (UPDRS III) scores of rs11931074 carriers were lower than those of noncarriers (SC: -0...
2018: Parkinson's Disease
Yoshiki Takamatsu, Masayo Fujita, Gilbert J Ho, Ryoko Wada, Shuei Sugama, Takato Takenouchi, Masaaki Waragai, Eliezer Masliah, Makoto Hashimoto
Lewy body diseases, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), are associated with a wide range of nonmotor symptoms (NMS), including cognitive impairment, depression and anxiety, sleep disorders, gastrointestinal symptoms, and autonomic failure. The reason why such diverse and disabling NMS have not been weeded out but have persisted across evolution is unknown. As such, one possibility would be that the NMS might be somehow beneficial during development and/or reproductive stages, a possibility consistent with our recent view as to the evolvability of amyloidogenic proteins (APs) such as α -synuclein ( α S) and amyloid- β (A β ) in the brain...
2018: Parkinson's Disease
Han Gil Seo, Sang Jun Park, Jiah Seo, Seong Jun Byun, Byung-Mo Oh
Objective: Although evidence and guidelines recommend appropriate rehabilitation from the beginning of diagnosis in patients with Parkinson's disease (PD), there is a lack of data addressing the utilization of rehabilitation therapies for these patients in practice. The aim of this study is to investigate the rate of rehabilitation therapy utilization over time in patients with PD using a nationwide cohort in Korea. Methods: Patients were identified using the registration code for PD in the program for rare, intractable disease from the National Health Insurance Service-National Sample Cohort database, which consists of 979,390 Korean residents...
2018: Parkinson's Disease
Margaret T M Prenger, Penny A MacDonald
Difficulty with emotion recognition is increasingly being recognized as a symptom of Parkinson's disease. Most research into this area contends that progressive cognitive decline accompanying the disease is to be blamed. However, facial mimicry (i.e., the involuntary congruent activation of facial expression muscles upon viewing a particular facial expression) might also play a role and has been relatively understudied in this clinical population. In healthy participants, facial mimicry has been shown to improve recognition of observed emotions, a phenomenon described by embodied simulation theory...
2018: Parkinson's Disease
Oriol De Fabregues, Alex Ferré, Odile Romero, Manuel Quintana, José Álvarez-Sabin
Background: Sleep problems in patients with advanced Parkinson's disease (PD) have a deleterious impact on quality of life. Objective: To assess the effect of levodopa-carbidopa intestinal gel (LCIG) infusion on sleep quality in advanced PD patients. Methods: Seven patients participated in a prospective pilot study. Before and after 6 months of LCIG infusion, an overnight polysomnography was performed and the Epworth Sleepiness Scale, fatigue scale, Pittsburgh Sleep Quality Index, Beck Depression Inventory, and the Hamilton Anxiety Rating Scale were administered...
2018: Parkinson's Disease
Hojoong M Kim, James B Leverenz, Daniel J Burdick, Sindhu Srivatsal, Jennifer Pate, Shu-Ching Hu, Steven P Millard, Marie Y Davis, Ali Samii, Cyrus P Zabetian
Background: The Washington State Parkinson Disease Registry (WPDR) was created to facilitate recruitment for Parkinson's disease (PD) research studies conducted in the Pacific Northwest. The success of registries that rely on self-report is dependent on the accuracy of the information provided by participants, particularly diagnosis. Objective and Methods: Our goal was to assess diagnostic accuracy within the WPDR cohort. We randomly selected and attempted to contact 168 of the 1,278 actively enrolled WPDR participants...
2018: Parkinson's Disease
C Buhmann, D Jungnickel, E Lehmann
Background: Stress reduction and relaxation exercises are therapeutically suggested to patients with Parkinson's disease (PD) and tremor, but data regarding efficacy or preferential methods are missing. Objective: To investigate the effect of a standardized stress management training (SMT) according to Kaluza on coping with tremor-boosting psychosocial stress factors. Methods: 8-week SMT was applied to 82 PD patients with tremor and 30 controls...
2018: Parkinson's Disease
John C Morgan, Rohit Dhall, Robert Rubens, Sarita Khanna, Suneel Gupta
Background: IPX066 is an extended-release (ER) oral formulation of carbidopa-levodopa (CD-LD). Following an initial peak at about one hour, plasma LD concentrations are maintained for about 4-5 hours. Objective: To present dosing factors that may affect the successful conversion to ER CD-LD from other LD formulations. Methods: Two-phase 3 studies of ER CD-LD vs. immediate-release (IR) CD-LD (ADVANCE-PD) and vs. CD-LD + entacapone (CLE; ASCEND-PD) in subjects with advanced PD included a 6-week, open-label conversion to ER CD-LD prior to treatment randomization...
2018: Parkinson's Disease
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"